The cost-effectiveness of irbesartan for hypertension

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Hypertension is a prevalent global health issue affecting adults and the elderly.
• Complications of hypertension are more frequent in patients with metabolic syndrome and Type 2 diabetes.
• Numerous drug classes exist for hypertension management, necessitating efficacy and economic evaluations.

Purpose of the Study:

• To review the effectiveness of irbesartan in preventing or delaying organ damage in hypertensive patients.
• To analyze the economic implications of using irbesartan for hypertension treatment.
• To compare irbesartan's efficacy and economic impact against other antihypertensive drugs.

Main Methods:

• Literature review of clinical trials and pharmacological studies on irbesartan.
• Analysis of data concerning organ damage prevention in hypertensive patients treated with irbesartan.
• Economic evaluation of irbesartan therapy in comparison to alternative antihypertensive agents.

Main Results:

• Irbesartan demonstrates significant antihypertensive efficacy.
• The drug has shown promise in preventing or delaying organ damage, especially in complex hypertensive patients.
• Economic analysis suggests potential cost-effectiveness in specific patient populations.

Conclusions:

• Irbesartan is a valuable therapeutic option for hypertension, particularly in patients with metabolic complexities.
• Further research into long-term organ protection and comprehensive cost-benefit analyses is warranted.
• Irbesartan offers a favorable profile for managing hypertension and its associated risks.